CONFIDENTIALNovelos Therapeutics, Inc. • January 31st, 2013 • Pharmaceutical preparations • New York
Company FiledJanuary 31st, 2013 Industry JurisdictionThis amended and restated letter (the ”Agreement”) constitutes the agreement between Burrill LLC (“Burrill” or the “Placement Agent”) and Novelos Therapeutics, Inc, (the “Company”), that Burrill shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Burrill would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement, the Subscription Agreem
COMMON STOCK PURCHASE WARRANTNovelos Therapeutics, Inc. • January 31st, 2013 • Pharmaceutical preparations • New York
Company FiledJanuary 31st, 2013 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on January __, 2018 (five (5) years from the effective date of the Company’s registration statement on Form S-1, SEC File No. 333-185053) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Novelos Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the common stock, par value $0.00001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued by the Company as of the date hereof